Collaborative Research Agreement between VivaZome Pty Ltd and ToolGen, Inc.
27 August 2019 Melbourne, Australia and Seoul, South Korea: VivaZome Therapeutics Pty Ltd (“VivaZome”) and ToolGen, Inc (“ToolGen”) have announced the execution of a collaborative research and option agreement to explore gene-editing of cells for enhanced exosome production.…
Nucleus Network expansion creates first global, multi-site early phase trial organisation with investment in USA-based phase I clinical trials organization, Prism Clinical Research.
27 August, 2019 Nucleus Network, Australia’s leading early-phase clinical research organization, is pleased to announce it has acquired a majority shareholding in Prism Clinical Research, a 52-bed, early-phase clinical research facility located in Minneapolis/St. Paul, Minnesota, USA. The…
NOX receives 2018/19 Federal Government R&D tax rebate
23 August 2019 Sydney, Australia. Noxopharm Limited (ASX: NOX) is pleased to announce that it has received $3.71M cash rebate as part of the Federal Government R&D Tax Incentive Scheme. Greg van Wyk, Noxopharm Chief Executive Officer, said,…
Applications open for Victorian Government Women’s Board Leadership Program
26 August 2019 Nominations close: Tuesday 10 September 2019 What is the Women’s Board Leadership Program? The Women’s Board Leadership Program encourages women to serve, stay, and excel on community and government boards. The program offers a range of governance…
PLEXOVAL exosome wound healing human study starts – Exopharm Limited
26 August 2019 Melbourne, Australia: Regenerative medicine company Exopharm Limited (ASX:EX1) announces the start of the PLEXOVAL Phase 1 study, the first human clinical trial using exosomes for wound healing. This is an important step forward as a…
Research Australia welcome Australian Academic and Researcher to its Board of Directors
22 August 2019 Research Australia has welcomed to its Board, Professor Melissa Little, Theme Director of Cell Biology at the Murdoch Children’s Research Institute, Program Leader of Stem Cells Australia, Professor, Department of Pediatrics, and Honorary Professor, Anatomy…
Largest ever study finds links in epilepsy genes – Melbourne University & Austin Health
2 August 2019 Researchers and patients from Austin Health and the University of Melbourne have been involved in the largest ever study looking at the genetic sequences of people with epilepsy. The international research, published this week in…
Lab-on-a-chip drives search for new drugs to prevent blood clots – RMIT University
20 August 2019 A tiny lab the size of a postage stamp could be the next big thing in the search for safer anti-clotting drugs to prevent heart attacks and strokes. The effectiveness of current anti-clotting medication can…
First Asian Regulatory Approvals Received for VivaGel® BV – Starpharma
15 August 2019 Melbourne, Australia: Starpharma today announced that it has received the first regulatory approvals in South East Asia for VivaGel® BV. Mundipharma will be rolling-out the product in Asia under the brand name BETADINETM BV Gel. BETADINETM BV Gel will…
Dr David Haylock joins VivaZome Therapeutics as Chief Scientific Officer
14 August 2019 Manufacturing development work begins at CSIRO VivaZome Therapeutics is pleased to announce that esteemed cell therapy scientist Dr David Haylock has joined the company as Chief Scientific Officer. Dr Haylock will lead the scientific and…
AdAlta Executive team changes
12 August 2019 The Board of AdAlta Limited (ASX:1AD), today announced that it has accepted the resignation of Ms Samantha Cobb as Chief Executive Officer and Managing Director. Over the last 12 years as founding CEO, Sam has…
Meta-Analysis Summary: Prolonged Cardiac Rhythm Monitoring and Secondary Stroke Prevention in Patients with Cryptogenic Cerebral Ischemia – Medtronic
12 August 2019 As published in Stroke, August 2019 You might be interested in a latest study published in Stroke (August). The study is the first outcome evidence available for long-term heart monitoring in patients with unexplained stroke.…
